52092-47-4Relevant articles and documents
INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
Paragraph 0217, (2016/09/26)
no abstract published
INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
Page/Page column 65, (2015/07/15)
Novel spirocyclic compounds of formula I: and pharmaceutically acceptable salts thereof are disclosed as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. Pharmaceutical compositions and methods of treatment are also included.
INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
Page/Page column 64, (2015/07/15)
Novel spirocyclic compounds of formula I: and pharmaceutically acceptable salts thereof are disclosed as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. Pharmaceutical compositions and methods of treatment are also included.
INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
Page/Page column 56, (2013/03/28)
This invention relates to compounds having structural Formula I: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kirl.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure
Amide compounds and medications containing the same technical field
-
Page/Page column 145, (2010/02/10)
The present invention provides to a novel compound having an ACAT inhibiting activity. The present invention relates to compounds represented by formula (I) wherein represents an optionally substituted divalent residue such as benzene, pyridine, cyclohexane or naphthalene, or a group,Het represents a 5- to 8-membered, substituted or unsubstituted heterocyclic group containing at least one heteroatom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, such as a monocyclic group, a polycyclic group or a group of a fused ring,X represents —NH—, an oxygen atom or a sulfur atom,Y represents —NR4—, an oxygen atom, a sulfur atom, a sulfoxide or a sulfone,Z represents a single bond or —NR5—,R4 represents a hydrogen atom, a lower alkyl group, an aryl group or an optionally substituted silyl lower alkyl group,R5 represents a hydrogen atom, a lower alkyl group, an aryl group or an optionally substituted silyl lower alkyl group, andn is integer of from 1 to 15, or salts or solvates thereof, and a pharmaceutical composition containing at one of these compounds.
AZOLE INHIBITORS OF CYTOKINE PRODUCTION
-
, (2008/06/13)
Compounds having the formula are useful for treating diseases that are prevented by or ameliorated with Interleukin-2, Interleukin-4, or Interleukin-5 production inhibitors.
2-SULFILIMINOPYRIDINES AND THEIR OXIDATION TO 2-NITROPYRIDINES
Rakitin, O. A.,Vlasova, O. G.,Khmel'nitskii, L. I.,Falyakhov, I. F.,Sobachkina, T. N.
, p. 1281 - 1283 (2007/10/02)
Sulfilimines of the pyridine series with electron-acceptor substituents in the ring were synthesized.It was shown that their oxidation with trifluoroperacetic acid results in the corresponding nitropyridines.The limitations of the methods were indicated.
1-Benzoyl-3-(aryloxy- or arylthiopyridinyl) urea compounds
-
, (2008/06/13)
The present invention is directed to 1-benzoyl-3-(aryloxy- or arylthio-pyridinyl)urea compounds useful as insecticides.
